Allergen News and Research

RSS

People with food allergies less likely to become infected with SARS-CoV-2, study finds

A National Institutes of Health-funded study has found that people with food allergies are less likely to become infected with SARS-CoV-2, the virus that causes COVID-19, than people without them. In addition, while previous research identified obesity as a risk factor for severe COVID-19, the new study has identified obesity and high body mass index (BMI) as associated with increased risk for SARS-CoV-2 infection.

1 Jun 2022

Key immunological changes that support peanut allergy remission in children discovered

Australian researchers have discovered the key immunological changes that support the remission of peanut allergy in children, paving the way for new, more targeted treatments.

25 May 2022

Using microfluidics and magnets to isolate rare, allergen-reactive white blood cells

Across the world, food allergies are on the rise. One of the most important cells in studying this ailment are basophils, which activate inflammation and other responses to allergens such as rashes, and sometimes, anaphylaxis.

23 May 2022

COVID-19 pandemic associated with increased anxiety and asthma symptoms in asthma sufferers

In the past two years, COVID-19 has provoked anxiety throughout the world for people worried they and their loved ones would get the virus and suffer tragic consequences.

5 May 2022

Researchers reveal why people with allergic asthma are protected from severe COVID

The vast majority of people infected with the omicron variant of SARS-CoV-2 experience mild cold-like symptoms, moderate flu-like symptoms, or no symptoms at all, but the virus is so transmissible that it still spread deep into lung tissue to cause severe disease and death in thousands of people in the United States in 2022 alone.

7 Apr 2022

Study sheds light on biomechanistic reasons why allergic asthma correlates with milder forms of COVID-19

An exciting study recently published in the PNAS underscores the role of a well-established cytokine IL-13 in protecting our cells against SARS-CoV-2.

31 Mar 2022

Researchers report progress en route to developing a hypoallergenic cat

Researchers at InBio (formerly Indoor Biotechnologies), a biotech company in Virginia, report progress en route to developing a hypoallergenic cat – or at least treating patients with allergies to the domestic cat – in a new article published online in The CRISPR Journal.

29 Mar 2022

IU researchers exploring new ways to treat seasonal or intermittent asthma

Researchers from Indiana University School of Medicine Department of Microbiology and Immunology are studying new ways to treat seasonal or intermittent asthma.

21 Mar 2022

New test greatly simplifies the diagnosis of allergies

Although allergies are widespread, their diagnosis is complex and, depending on the type of allergy, the prospects of success with therapy are not always clear.

21 Mar 2022

Specific variant of the HLA-DPB1 gene linked with poor response to allergen immunotherapy

Although sublingual immunotherapy (SLIT) has become an effective treatment option for many allergies, about 20-30% of patients don’t respond to SLIT for Japanese cedar pollinosis–a highly common disease.

7 Mar 2022

Microneedle treatments could significantly desensitize people with food allergies

Treating peanut allergy with microneedles could significantly improve desensitization by directly targeting the allergen to the skin, providing greater protection from severe allergic reactions for millions of people, a new study suggests.

4 Mar 2022

Clinical trial shows encouraging results with fecal microbiota transplants for peanut-allergic patients

Peanut allergies are hard to treat and can cause fatal or near-fatal anaphylactic reactions. People usually don't outgrow peanut allergy, requiring lifelong scrutiny of food labels to avoid even small traces of peanut.

27 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Two peanut allergy treatments for children found to be highly effective at inducing remission

Researchers have discovered two peanut allergy treatments for children that are both highly effective at inducing remission.

7 Feb 2022

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

The majority of young children treated with peanut immunotherapy achieved desensitization after two and a half years of treatment, and one in five remained in remission 26 weeks after treatment ended, according to a randomized controlled trial published in The Lancet.

20 Jan 2022

Development of a glycoprotein multi-epitope subunit vaccine candidate against South-African SARS-CoV-2 strains

In a new study, scientists focused on the SARS-CoV-2 Beta variant and used computational methods to design and develop effective glycoprotein multi-epitope subunit vaccine candidates, based on the old and the new Beta virus strains.

20 Jan 2022

International approaches to tackling food fraud

In this interview, we spoke to key members of the Food Authenticity Network to find out more about the increasing problem of food adulteration and the collaborations being made to address it.

From Bruker BioSpin - NMR, EPR and Imaging 11 Jan 2022

Scientists unravel how LPS prevents or promotes development of allergic disease

Immunologists have long been baffled by LPS, the bacterial lipopolysaccharide that helps form the cell walls of Gram-negative bacteria.

5 Jan 2022

Measuring airway inflammation when diagnosing and treating asthma patients

In this interview, Carol Stonham, the head of a Locality Based FeNO referral service, talks to NewsMed about measuring airway inflammation when diagnosing and treating asthma patients.

From Bedfont® Scientific Ltd 21 Dec 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021